role of calcitonin gene related peptide FAQ

Calcitonin gene-related peptide (CGRP) levels increase during acute migraines. Triptans, which are normally used during migraine attacks, primarily reduce the CGRP level. This decrease corresponds with migraine relief. Treatment with a CGRP receptor antagonist relieves migraines through the following possible mechanisms:

Calcitonin gene-related peptide (CGRP) is a neuropeptide, which is a type of protein that acts as a signaling molecule in the brain. CGRP is a chemical messenger made up of small chains of amino acids that are synthesized and released by neurons or nerve fibers. The function of the neurons is to convey messages or commands from the brain to the various tissues of the body.

Calcitonin gene-related peptide (CGRP) is produced from the cell body of nerve cells or neurons. When the nerves are activated, CGRP and other neuropeptides are released that promote the release of inflammatory mediators, leading to pain, swelling, and other signs of inflammation. CRPG levels increase in conditions such as:

The effects of calcitonin gene-related peptide (CGRP) in the body include:

When released in excess, calcitonin gene-related peptide (CGRP) causes intense inflammation in coverings of the brain (meninges). The mechanism of action of CGRP antagonists is by blocking CGRP receptors of the nerve cells, which trigger intense pain and activate the CGRP cascade. CGRP antagonists bind to CGRP receptors and do not allow the binding of CGRP to its receptor. Some CGRP antagonists include: